An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.

被引：0
|
作者：
Bekaii-Saab, Tanios S.
Yarchoan, Mark
Ahmed, Muneeb
Cohan, David Michael
Ma, Wen Wee
机构：
[1] Mayo Clin Arizona, Phoenix, AZ USA
[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA USA
[4] Replimune Inc, Milford, CT USA
[5] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS623
引用
收藏
页码：TPS623 / TPS623
页数：1
相关论文
共 50 条
  • [21] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).
    Peer, Avivit
    Neumann, Avivit
    Keizman, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Kudo, Masatoshi
    Lau, George
    Kelley, Robin Kate
    Furuse, Junji
    Sukeepaisarnjaroen, Wattana
    Kang, Yoon-Koo
    Dao, Tu V.
    De Toni, Enrico N.
    Rimassa, Lorenza
    Breder, Valeriy Vladimirovich
    Vasilyev, Alexander
    Heurgue, Alexandra
    Tam, Vincent
    Mody, Kabir
    Thungappa, Satheesh Chiradoni
    He, Philip
    Negro, Alejandra
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
    Shen, L.
    Ajani, J. A.
    Kim, S-B.
    Van Cutsem, E.
    Guo, B.
    Song, J.
    Paton, V.
    Kato, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
    Li, B-K.
    Yuan, Y.
    Qiao, L.
    He, W.
    Wang, G.
    Chen, H.
    Zhang, B.
    Fuxi, H.
    Qiu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S596 - S596
  • [25] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
    Zhang, Bo
    Wang, Xi
    Zhu, Lingjun
    Li, Qun
    Liu, Yun
    Qi, Ling
    Shu, Yongqian
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
    Shen, Lin
    Ajani, Jaffer A.
    Kim, Sung-Bae
    Van Cutsem, Eric
    Guo, Baohong
    Song, James
    Paton, Virginia
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [28] A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
    Cheng, A-L.
    Yen, C-J.
    Okusaka, T.
    Ikeda, M.
    Hsu, C-H.
    Wu, S-Y.
    Morizane, C.
    Hashimoto, Y.
    Ueshima, K.
    Ohtomo, T.
    Tanaka, T.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
    Thomas, Melanie B.
    Garrett-Mayer, Elizabeth
    Anis, Munazza
    Anderton, Kate
    Bentz, Tricia
    Edwards, Andie
    Brisendine, Alan
    Weiss, Geoffrey
    Siegel, Abby B.
    Bendell, Johanna
    Baron, Ari
    Duddalwar, Vinay
    El-Khoueiry, Anthony
    ONCOLOGY, 2018, 94 (06) : 329 - 339
  • [30] Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
    Sun, Y.
    Wu, Y. -L.
    Zhou, C. -C.
    Zhang, L.
    Zhang, L.
    Liu, X. -Y.
    Yu, S. -Y.
    Jiang, G. -L.
    Li, K.
    Qin, S. -K.
    Ma, S. -L.
    Han, L.
    Quinlivan, M.
    Orlando, M.
    Zhang, X. -Q.
    LUNG CANCER, 2013, 79 (02) : 143 - 150
12345